By overproducing and purifying a fully human monoclonal antibody specifically targeting GRP94, we demonstrated that the antibody targeting of cell surface GRP94 potently reduces the tumor growth of cetuximab-resistant CRC, without severe toxicity. This evidence concerns the gene HSP90B1 and neoplasm.